The reduction in the leptin-adiponectin ratio with remogliflozin has been reported to improve the metabolic health of adults with overweight or obesity but not diabetes, proposing this as an additional mechanism of body weight reduction with SGLT2 inhibitors (19, 26). The gene discussed is ADIPOQ; the disease is diabetes mellitus.